Short Course of Omeprazole
- 1 October 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 35 (4) , 307-314
- https://doi.org/10.1097/00004836-200210000-00006
Abstract
Noncardiac chest pain (NCCP) presents as a frequent diagnostic challenge, with patients tending to use a disproportionate level of health care resources. Gastroesophageal reflux disease (GERD) is the most frequent cause of NCCP. To test the efficacy of a potent acid-suppressing agent as a diagnostic test in the evaluation of NCCP and to compare it with three commonly used tests. Eighteen men and 24 women, aged 22 to 77 years, who presented with recurrent chest pain complaints of a noncardiac etiology, as determined by rest/stress perfusion imaging with technetium Tc99m sestamibi (MIBI), were enrolled in a prospective, double-blinded, placebo-controlled, crossover trial using high-dose omeprazole. Thirty-seven patients completed both arms of the trial. Findings were compared with those of endoscopy, manometry, and ambulatory 24-hour two-channel esophageal pH monitoring. All patients underwent initial diagnostic upper endoscopy, esophageal manometry, and 24-hour pH monitoring. Patients were then randomly assigned to either placebo or omeprazole (40 mg/d orally twice daily) for 14 days, washed out for 21 days, and then crossed over. Patient's symptoms were determined using a Visual Analogue Scale to measure the severity of chest pain before and after each period. Seventy-one percent of patients in the omeprazole arm reported improved chest pain, whereas only 18% in the placebo arm did. Abnormal results on manometry (20%), 24-hour pH monitoring (42%), or endoscopy with visual evidence of esophagitis (26%) were found less frequently. Combination of the three tests did not significantly increase their usefulness. In NCCP patients with GERD, as defined by positive results on a 24-hour pH test or presence of esophagitis on endoscopy, omeprazole treatment led to a response in 95% of patients, whereas 90% of GERD-positive patients treated with placebo did not respond. Of NCCP patients determined to be GERD negative, 39% responded to omeprazole. Omeprazole as a first diagnostic tool in the evaluation of MIBI-negative NCCP is sensitive and specific for determining the cause of NCCP. Endoscopy, manometry, and 24-hour pH monitoring were not only less sensitive in diagnosing NCCP, but they were significantly more expensive.Keywords
This publication has 10 references indexed in Scilit:
- The clinical and economic value of a short course of omeprazole in patients with noncardiac chest painGastroenterology, 1998
- Value of Acute Rest Sestamibi Perfusion Imaging for Evaluation of Patients Admitted to the Emergency Department With Chest PainJournal of the American College of Cardiology, 1997
- Empiric therapy for gastroesophageal reflux diseaseArchives of internal medicine (1960), 1995
- Diagnosis and Treatment of Patients With Gastroesophageal Reflux and Noncardiac Chest PainSouthern Medical Journal, 1994
- Acute noncardiac chest pain in a coronary care unitGastroenterology, 1992
- Utility of upper endoscopy in the evaluation of noncardiac chest painGastrointestinal Endoscopy, 1991
- Esophageal Testing of Patients with Noncardiac Chest Pain or DysphagiaAnnals of Internal Medicine, 1987
- 24-Hour recording of esophageal pressure and pH in patients with noncardiac chest painGastroenterology, 1986
- THE OESOPHAGUS AS A CAUSE OF RECURRENT CHEST PAIN: WHICH PATIENTS SHOULD BE INVESTIGATED AND WHICH TESTS SHOULD BE USED?The Lancet, 1985
- Esophageal Function in Patients with Angina-Type Chest Pain and Normal Coronary AngiogramsAnnals of Surgery, 1982